How large is the dasatinib drugs market, and what is its growth trajectory?
The dasatinib drugs market size has grown strongly in recent years. It will grow from $1.45 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to increase in prevalence of chronic myeloid leukemia (CML), growth in targeted cancer therapies, growth in research on tyrosine kinase inhibitors (TKIS), increase in investment in oncology research, and rise in number of clinical trials.
The dasatinib drugs market size is expected to see strong growth in the next few years. It will grow to $2 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing investment in oncology drug pipelines, rising prevalence of drug resistant leukemia cases, growing availability of generic dasatinib drugs, increasing focus on minimizing side effects of chemotherapy, and increasing awareness and early diagnosis of leukemia. Major trends in the forecast period include adoption of personalized medicine, implementation of companion diagnostics, development of new formulations, advancements in combination therapies, and development of biosimilars.
Get Your Free Sample of The Global Dasatinib Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19023&type=smp
What are the key forces behind the dasatinib drugs market’s growth in recent years?
The increasing prevalence of chronic myeloid leukemia (CML) is expected to propel the growth of the dasatinib drug market going forward. Chronic myeloid leukemia (CML) is a type of cancer that affects the bone marrow and blood and is characterized by the abnormal growth of white blood cells. The rising prevalence of chronic myeloid leukemia (CML) is largely driven by lifestyle demographics, unhealthy eating, and increasing environmental risk factors. Dasatinib drugs are helpful in treating chronic myeloid leukemia (CML) by inhibiting the activity of BCR-ABL (gene fusion), a tyrosine kinase protein produced by the Philadelphia chromosome mutation, which drives the uncontrolled growth of cancerous white blood cells. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based health organization dedicated to eliminating cancer, chronic myeloid leukemia (CML) increased to 8,930 compared to 8,860 in 2022 in the United States. Therefore, the increasing prevalence of chronic myeloid leukemia (CML) is driving the dasatinib drug market.
What are the major segments of the dasatinib drugs market?
The dasatinib drugsmarket covered in this report is segmented –
1) By Product Type: Tablets, Oral Suspension, Other Products
2) By Indication: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Other Indications
3) By End User: Hospitals, Specialty Clinics, Home Healthcare
Subsegments:
1) By Tablets: 20 mg Tablets, 50 mg Tablets, 70 mg Tablets, 80 mg Tablets
2) By Oral Suspension: 20 mg Or 5 mL Oral Suspension, 40 mg Or 5 mL Oral Suspension
3) By Other Products: Injectable Formulations, Combination Therapies, Generic Dasatinib Products
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/dasatinib-drugs-global-market-report
Which companies dominate the dasatinib drugs market?
Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sandoz Group AG, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, MSN Laboratories Pvt. Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP
What major trends will shape the dasatinib drugs market during the forecast period?
Major companies operating in the dasatinib drugs market are focusing on developing generic drugs to expand their market share, provide cost-effective treatment options, and increase accessibility for patients. Generic medicines in the dasatinib market offer more affordable treatment options, improving patient access and promoting competition while reducing healthcare costs for patients. For instance, in September 2024, Apotex Corp., a Canada-based pharmaceutical company, launched the first generic version of Sprycel dasatinib in the United States to treat certain types of leukemia in adults and children. This cost-effective alternative improves access to high-quality treatment options. Its introduction marks a significant step in increasing competition and lowering prices in the dasatinib market.
What are the key regional dynamics of the dasatinib drugs market, and which region leads in market share?
North America was the largest region in the dasatinib drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Dasatinib Drugs Market Report 2025 Offer?
The dasatinib drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Dasatinib drugs refer to a type of targeted therapy known as tyrosine kinase inhibitors, primarily used to treat blood cancers, such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). They work by blocking proteins that drive cancer cell growth, helping to slow disease progression. This leads to improved survival rates and better management of the disease.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19023
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
